Transforming our business to capitalise on the growth in the global healthcare market

Growth in the global healthcare market is expected to accelerate to approximately 5-6% per annum with the market projected to exceed $1.4 trillion by 20221. The US market is set to account for 45% of this projected spend. Key drivers of this growth include: a sustained increase in FDA product approvals; a continued shift towards the launch of more complex specialty medicine; and the significant growth of orphan drugs as the pharmaceutical industry moves to address smaller patient groups with significant unmet needs.

In addition, rising healthcare and drug costs are driving demand for quality, cost effective and flexible solutions.

Demand for outsourcing is also increasing as clients seek specialist expertise, services and quality. In particular small and mid-sized pharmaceutical and biotech companies who lack commercial infrastructures when developing specialty medicines seek expert outsourcing solutions.

UDG Healthcare’s broad portfolio of skills and services ensures it is uniquely positioned to meet the needs of its clients across all stages of the product lifecycle.

While every outlook involves a degree of uncertainty, including the growth potential of new products and a secondary patent cliff, the overall conditions in the global healthcare market remain positive for the future.

1. 2018 and Beyond: Outlook and Turning Points, IQVIAInstitute, March 2018.
2. World Preview 2018, Outlook to 2024, Evaluate Pharma, June 2018.
3. Medicines Use and Spending in the US, A review of 2017 and Outlook to 2022, IQVIAInstitute, April 2018.

Divisional Specific Market Opportunities

Ashfield Advisory

KEY GROWTH DRIVERS:

  • Increasing outsourcing penetration
  • Changes and increasingly complex specialty therapies and launches
  • Growing demand for data and informed research to improve decision making
  • Increasing number of molecules in development and positive FDA approval outlook
Estimates Market Size* $2.9bn

Ashfield Communications

KEY GROWTH DRIVERS:

  • Increasing outsourcing penetration
  • Growth of specialty products leading to increased demand for multichannel and digital communications
  • Increasing number of molecules in development and positive FDA approval outlook
  • Migration to direct patient engagement
  • Growth in orphan drug and rare diseases
Estimates Market Size* $7.3bn

Ashfield Commercial & Clinical

KEY GROWTH DRIVERS:

  • Significant potential for increased outsourcing
  • Increasing demand for innovative models, multi-channel offerings and multi-country solutions
  • Growth of specialty products leading to increased complexity and support requirements 
  • Increasing importance of patient adherence
  • Increasing number of molecules in development and positive FDA approval outlook
Estimated Market Size* $6.1bn

Sharp Commercial Packaging

KEY GROWTH DRIVERS:

  • Significant potential for increased outsourcing
  • Demand for secondary packaging of injectable products
  • Increasing requirement to access specialist technology solutions and capabilities
  • Client demand for deeper strategic relationships with contract partners
US & EU Estimated Market Size* $5bn-7bn

Sharp Clinical Services

KEY GROWTH DRIVERS:

  • Increasing outsourcing penetration
  • Demand from emerging and mid-size pharma companies for end-to-end integrated service offerings
  • Greater demand for digital solutions including Clinical IRT and Serialisation

* Sources for market sizes: Derived from BCG, Deloitte and internal analysis.

US & EU Estimated Market Size* $6bn-8bn